Published in Cancer Weekly, July 30th, 2002
VEGF is an important modulator of neovascularization, or angiogenesis in solid tumors. Cancer researchers have proposed that antisense oligonucleotides specifically targeting VEGF production could be used to diminish tumor vascularity. Researchers at the University of Florida in Gainesville report they have been able to significantly slow renal carcinoma tumor growth in nude mice by giving them systemic treatments of antisense oligonucleotides to VEGF.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.